Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer
FRAMINGHAM, MA / ACCESSWIRE / October 11, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the signing of a patent assignment from CLS Therapeutics, Inc. ("CLS") to Xenetic related to Xenetic's previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets. In consideration of the patent assignment, Xenetic will also issue 850,000 shares of common stock to CLS.
Xenetic Biosciences, Inc., Tuesday, October 11, 2022, Press release picture
"Our team remains intent on driving the DNase technology platform forward with the goal of improving outcomes of existing therapeutic agents in multiple solid tumor indications for which existing therapeutic agents have not been proven to be effective. Our collaboration with Volition and CLS has provided us with research and development partners with expertise and capabilities to help drive the DNase-Armored CAR T program forward. We are excited to continue building on the progress we've made thus far and on taking the next steps forward in executing on our plans to advance the DNase technology," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.
The Company's collaboration with Volition is an early exploratory program to evaluate the potential combination of Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform to develop proprietary adoptive cell therapies potentially targeting multiple types of solid cancers for which current CAR T cell therapies have shown limited or no effect. Under the terms of the collaboration agreement, Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration.
Story continues
Epigenetically modified nucleosomes are present on tumor cell surfaces and within the tumor microenvironment of multiple types of solid cancers, and thus these nucleosomes may represent generalizable tumor antigens that are not limited to a single cancer type. Volition's Nu.Q technology can specifically recognize and target epigenetically modified nucleosomes, while Xenetic's DNase-Armored CAR T platform is designed to enhance the function of CAR T cells within solid tumor microenvironments.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are implicated in multiple pathways of cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors.
The Company is also developing its personalized CAR T platform technology, XCART, to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas.
For more information, please visit the Company's website at http://www.xeneticbio.com and connect on Twitter, LinkedIn, and Facebook.
Xenetic Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including, but not limited to, statements regarding: the patent assignment and the collaboration agreement with Volition and CLS, including regarding the issuance of shares of common stock to CLS, the collaboration providing us with research and development partners with expertise and capabilities to help drive the DNase-Armored CAR T program forward, our expectations regarding continuing to build on the progress we've made thus far and on taking the next steps forward in executing on our plans to advance the DNase technology, our belief regarding the potential combination of Volition's Nu.Q technology and Xenetic's DNase-Armored CAR T platform leading to the development of proprietary adoptive cell therapies potentially targeting multiple types of solid cancers for which current CAR T cell therapies have shown limited or no effect, the terms of the collaboration agreement, pursuant to which Volition will fund a research program and the two parties will share proceeds from commercialization or licensing of any products arising from the collaboration, and the potential for nucleosomes to represent generalizable tumor antigens that are not limited to a single cancer type; all statements regarding our expectations with respect to our DNase oncology platform, including our expectations to remain intent on driving the DNase technology platform forward with the goal of improving outcomes of existing therapeutic agents in multiple solid tumor indications for which existing therapeutic agents have not been proven to be effective, our expectations to focus on advancing the systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally advanced or metastatic solid tumors, and our belief that the DNase platform is designed to enhance the function of CAR T cells within solid tumor microenvironments; and plans regarding our personalized CAR T platform technology, XCART, being used to develop cell-based therapeutics targeting the unique B-Cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-Cell lymphomas. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from the collaboration agreement with Volition and CLS; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform or the patent assignment; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase, XCART or PolyXen technologies; (5) the ability of the Company to implement its business strategy; and (6) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, such as the COVID-19 outbreak, and geopolitical events, such as the Russian invasion of Ukraine, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.
Xenetic Contact:JTC Team, LLCJenene Thomas(833) 475-8247xbio@jtcir.com
SOURCE: Xenetic Biosciences, Inc.
View source version on accesswire.com: https://www.accesswire.com/719815/Xenetic-Biosciences-Inc-Announces-Signing-of-Patent-Assignment-Related-to-Collaboration-With-VolitionRx-Limited-and-CLS-Therapeutics
Follow this link:
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics - Yahoo Finance
- The Role of Epigenetics and Contributing Impact of Stress, Multigenerational, and Developmental Factors in Opiate ... - Cureus - February 8th, 2024
- About Epigenetics | Johns Hopkins Institute of Genetic Medicine - November 16th, 2023
- What is Epigenetics? - Bruce H. Lipton, PhD - January 4th, 2023
- Why Epigenetics Contradicts Evolutionary Theory | Evolution News - December 18th, 2022
- Epigenetics in Psychology | Noba - November 24th, 2022
- Epigenetics: Definition, Mechanisms and Clinical Perspective - November 24th, 2022
- Researchers Find that Moms Pass On Additional Epigenetic Information To Their Children - WhatIsEpigenetics.com - October 13th, 2022
- Prestigious award advances OHSU research on impact of drug use over generations - OHSU News - October 13th, 2022
- Hoylake doctor launches test that detects diseases before they appear - Wirral Globe - October 13th, 2022
- Understanding the Epigenetics of Childhood Trauma - Psych Central - October 4th, 2022
- Epigenetic therapy promotes spinal cord regeneration in mice following injury - RegMedNet - October 4th, 2022
- ORYZON to Give Updates on Corporate Progress in October - Yahoo Finance - October 4th, 2022
- InvestmentPitch Media Video Discusses Resverlogix and its Focus on Apabetalone's Future Development for the Prevention and Treatment of Post COVID-19... - October 4th, 2022
- Cardio Diagnostics To Sponsor, Participate in the American Heart Association's 2022 Metro Chicago Heart Walk - Yahoo Finance - September 16th, 2022
- Book review: Daughters and the stories they carry - Yahoo News - September 16th, 2022
- Inherent Biosciences raises funding to expand fertility care though epigenetics - VatorNews - September 8th, 2022
- 10 wellness retreat trends to know about - Cond Nast Traveller - September 8th, 2022
- Spotlight: Women in Science: Dr. Judith Kassis on Pursuing the Unexpected - National Institute of Child Health and Human Development - September 8th, 2022
- Epigenetic Information Passed On to Offspring More Frequently Than Once Thought - Technology Networks - August 22nd, 2022
- New discovery shows you may inherit more from your mom than you think - EastMojo - August 22nd, 2022
- New Technology to Understand Cell Types and How Diseases Develop - Yale University - August 22nd, 2022
- Research Roundup: Fat Cell Hormone Slows Liver Tumor Growth and More Research News - BioSpace - August 22nd, 2022
- De-extinction? Plans to revive Tasmanian tiger triggers... - The American Bazaar - August 22nd, 2022
- Epigenetics in Health and Disease - PubMed - August 14th, 2022
- Clinical Epigenetics | Home page - August 14th, 2022
- Efficacy of Neoadjuvant Immunotherapy on Breast Cancer is Independent of Race - Pharmacy Times - August 14th, 2022
- Your True Age Might Not Be Your Birthdate And Thats Good News - Goalcast - August 14th, 2022
- Epigenetics Market is Predicted to Hit $6460.5 Million Value by 2030, says P&S Intelligence - PR Newswire UK - July 27th, 2022
- ORYZON Collaborates with the CMT Research Foundation in the US - Yahoo Finance - July 27th, 2022
- What is schizophrenia? Common myths and misconceptions around the mental illness - The Mirror - July 27th, 2022
- What gene changes and blood could tell us about the opioid crisis - UCI News - July 19th, 2022
- Epigenetics Is The Key To Treating Complex Diseases; Dr. Nirmalya Saha Is Using It To Unlock Cancer Treatment And More - EconoTimes - July 19th, 2022
- Heatstroke stresses the body years after the original heat illness - University of Florida - July 19th, 2022
- Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma... - July 19th, 2022
- Genetics proposes, epigenetics disposes: how our approach to human health changes in the 21st century and how CRISPR-Cas is involved - Digital Journal - June 22nd, 2022
- Zenith Epigenetics Triple Negative Breast Cancer Clinical Data Highlighted in an Oral Discussion at the American Society of Clinical Oncology... - June 22nd, 2022
- The relationship between P16INK4A and TP53 promoter methylation and the risk and prognosis in patients with oesophageal cancer in Thailand |... - June 22nd, 2022
- Omega Therapeutics (OMGA) Research Analysts' Weekly Ratings Changes - Defense World - June 13th, 2022
- Introducing Cantata Bio, Inventive Multimodal Solutions for Accelerating Genome-based R&D - Business Wire - June 13th, 2022
- Plant biologist nominated for prestigious early career award - University of Georgia - June 13th, 2022
- Julee Cruise's Career: How and where to watch Twin Peaks and all her TV appearances - Bolavip US - June 13th, 2022
- Hitting the Pro Race Track: Onovi Health Adds Marko Radiic, Professional Race Car Driver & Entrepreneur, as a Brand Ambassador - PR Newswire - June 13th, 2022
- Epigenetics: Definition & Examples | Live Science - June 4th, 2022
- Genetics and Epigenetics of Addiction DrugFacts | National Institute on ... - June 4th, 2022
- Epigenetics Market is Growing Rapidly with Recent Demand, Trends, Development, Revenue and Forecast to 2029 The Greater Binghamton Business Journal -... - June 4th, 2022
- Epigenetics at the Intersection of COVID-19 Risk and Environmental Chemical Exposures - DocWire News - June 4th, 2022
- Global Epigenetics Instrument Market 2022 Covid 19 Impact on Top countries data |Illumina, Thermo Fisher, Diagenode The Greater Binghamton Business... - June 4th, 2022
- Global Biomarkers Market Outlook & Forecast 2022-2027: Increase In Number of Pipeline Biomarkers & Rising Adoption of Biomarkers In Disease... - June 4th, 2022
- Many African Americans face unresolved trauma of racism and enslavement; It's affecting their health - ideastream - June 4th, 2022
- Zenith Epigenetics Announces Initiation of a Phase 2b Triple Negative Breast Cancer (TNBC) Clinical Trial - BioSpace - May 15th, 2022
- Gene edited rats cured of anxiety and alcoholism | SYFY WIRE - Syfy - May 15th, 2022
- Dreams on Fire sheds light on epigenetics, collective trauma of genocide traveling through generations - Armenian Weekly - May 2nd, 2022
- NEAR science: good for what ails stressed communities - NUjournal - May 2nd, 2022
- Digital biomarkers - An Emerging tool in precision Medicines. The Biomarkers Market to Reach $86 Billion by 2027 - Arizton - Yahoo Finance - May 2nd, 2022
- Sprint Bioscience's NIMA program is focused on the target protein NNMT and will be launched at the BIO International convention - Marketscreener.com - May 2nd, 2022
- Post-Doctoral Associate in the Center for Genomics and Systems Biology job with NEW YORK UNIVERSITY ABU DHABI | 291713 - Times Higher Education - May 2nd, 2022
- Womb with a View: On the Science of Maternal Effects - lareviewofbooks - April 19th, 2022
- Molecular Biology Enzymes, Kits & Reagents Market likely to bring in approximately US$ 22000 Million revenues by 2026-end Political Beef -... - April 19th, 2022
- Type 2 diabetes on the rise among Wisconsin children - Iron Mountain Daily News - April 19th, 2022
- January 2022: Exposures, diverse populations, and epigenetics merge in grantee's lab - Environmental Factor Newsletter - January 5th, 2022
- Research Roundup: Why mRNA Vaccines are So Good Against Severe COVID-19 and More - BioSpace - January 5th, 2022
- Epigenetics - Genome.gov - December 24th, 2021
- Genetics, Epigenetics, and Cancer: What Data Are We Missing? - AJMC.com Managed Markets Network - December 24th, 2021
- Can epigenetics help solve the puzzle between concomitant cardiovascular injury and severity of COVID-19? - DocWire News - December 24th, 2021
- Genomics Market Revenue to Cross US$ 49996.15 by 2027: The Insight Partners - Digital Journal - December 24th, 2021
- Hydra regrow their heads and live forever due to epigenetics - Cosmos Magazine - December 10th, 2021
- Epigenetics Market to Garner US$ 2611.57 MN, Globally, by 2025 at 13.6% CAGR: The Insight Partners - Digital Journal - December 10th, 2021
- Research Associate or Research Assistant in Medical and Molecular Genetics job with KINGS COLLEGE LONDON | 274309 - Times Higher Education (THE) - December 10th, 2021
- Newpath Commits $350 Million to Fund the Next Good Things in the Life Sciences - BioSpace - December 10th, 2021
- Wind Turbine Market Development Overview And Analysis Till 2030- Market.Biz - Digital Journal - December 10th, 2021
- Cancer Testing Product Market to Witness Growth Acceleration | Epigenetics Ag, Techlab, Positive Bioscience Energy Siren - Energy Siren - November 22nd, 2021
- How can students make the best of their anxiety? - The Medium - November 22nd, 2021
- Epigenetic Study Links Smoke Exposure in Early Life to Advanced Aging - WhatIsEpigenetics.com - October 28th, 2021
- Salarius Pharmaceuticals (SLRX) is Developing a Novel LSD1 Inhibitor, Positioning it as a Significant Mover in Epigenetics-Based Cancer Therapies -... - October 28th, 2021
- Epigenetics-Based Kits Market To Witness High Growth In Near Future IMIESA - IMIESA - October 28th, 2021
- Epigenetics Diagnostic Market to Witness Growth Acceleration | Qiagen, Abcam plc, Novartis AG, Thermo Fisher Scientific IMIESA - IMIESA - October 28th, 2021
- LXRepair, Gustave Roussy Ink Research Partnership in Personalized Radiotherapy - Precision Oncology News - October 28th, 2021
- Van Andel Institute, Maine Medical Center Research Institute scientists earn $9.6 million Transformative Research Award from National Institutes of... - October 5th, 2021
- Epigenetics could reveal if you had a 'vanishing twin' - Popular Science - October 5th, 2021
- Epigenetics: Conducting The Symphony Of Genetics - Forbes - August 5th, 2021